Literature DB >> 19730247

Successful use of recombinant factor VIIa in a preterm infant with life-threatening haematuria.

Kirstin Faust1, Birthe Tröger, Fritz Kahl, Marius Schumacher, Wolfgang Göpel, Christoph Härtel.   

Abstract

We report the case of a preterm male infant with a gestational age of 28 + 1 weeks and birth weight of 715 g who presented with life-threatening haematuria on day 28 of life. The haematuria was unresponsive to administration of platelet concentrates and fresh frozen plasma, but then successfully treated with recombinant factor VIIa. The resulting obstructive uropathy was managed by continuous bladder irrigation through suprapubic and urethral catheters. No other adverse affects were noted, and the boy was discharged from the hospital on day 108 of life.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19730247     DOI: 10.1097/MBC.0b013e32832f6c40

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN: 0957-5235            Impact factor:   1.276


  1 in total

1.  Recombinant Activated Factor VIIa (rFVIIa) Treatment in Very-Low-Birth-Weight (VLBW) Premature Infants with Acute Pulmonary Hemorrhage: A Single-Center, Retrospective Study.

Authors:  Hese Cosar; Halil Isik; Salih Cagrı Cakır; Nese Yar; Bulent Goksen; Hakan Tokbay; Hasan Kertmen; Nihal Erdoğan; Ikbal Durak
Journal:  Paediatr Drugs       Date:  2017-02       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.